ClinicalTrials.gg
CompletedNCT00237484PegadeUpdated Aug 26, 2020

Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)

A Phase 3 interventional study of Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin and Combination of (a) pegylated interferon alfa-2b and (b) ribavirin in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-08-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
22nd of 39
89 · median 99
Started
2005
with 7 others
Phase 3
22 of 40
none open now
Registered
6th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 22nd largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2005, is one of 22 in phase 3, and was the 6th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This is a Phase IIIB, randomized, prospective, multicenter, single-country, open-label, controlled pilot trial designed to evaluate the effect of infliximab induction therapy on sustained virologic response (SVR) to treatment with pegylated interferon alfa-2b plus ribavirin in a group of 96 therapy-naïve subjects with genotype 1 hepatitis C virus (HCV) infection and high serum tumor necrosis factor (TNF)-alpha values.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

Keywords

  • pegylated interferon alfa-2b
  • ribavirin
  • infliximab
  • chronic hepatitis C
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • Subjects must be 18 to 65 years of age.
  • genotype 1 (including mixtures of subtypes of genotype 1).
  • Naïve to interferon (any formulation) and ribavirin.
  • Serum TNF-alpha >300 pg/mL(single measure at Pre-Screen Visit).
  • HCV ribonucleic acid (RNA) positive.
  • Any (ALT) level.
  • Fasting glucose should be 3.8-6.2 mmol/L. Results between 6.3-7.8 mmol/L require a \<=8.5%. All diabetic subjects must have an HbA1c \<=8.5%, whether on medication or diet controlled.
  • Liver within 24 months of enrolment demonstrating Stage 0-3 fibrosis (Metavir System).
  • Compensated liver disease with the following minimum hematological, biochemical, and serological criteria at the screen visit (WNL = within normal limits):

    • values of equal or more than 12 g/dL for females and 13 g/dL for males.
    • White blood cell (WBC) count equal to or more than 3,000/mm**3
    • equal to or more than 1,500/mm**3
    • count equal to or more than 80,000/mm**3
    • Total WNL
    • Indirect bilirubin WNL (unless non-hepatitis related factors such as Gilbert's disease explain an indirect bilirubin rise). In such cases indirect bilirubin should be less than or equal to 50 µmol/L
    • Albumin WNL
    • Serum creatinine WNL
  • Women of (includes women who are less than 1 year and women who become sexually active) must be willing to use an acceptable method of , deemed acceptable by the investigator, (e.g., hormonal contraceptive, medically prescribed intrauterine device (IUD), condom in combination with spermicidal) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
  • Subjects must understand and be able to adhere to the dosing and visit schedules, and agree to record, study medication compliance, concomitant medications, and adverse events accurately and consistently in a daily diary.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Subjects who have not observed the designated for any of the prohibited medications.
  • Subjects who have used any product within 30 days prior to enrollment.
  • Acute infection defined as infection for \<6 months.
  • Male partners to/or Heterosexually active women of not practicing a highly effective form of .
  • Positive screening for tuberculosis (TB) or Tuberculin Skin Test > 5mm.
  • History or presence of cirrhosis (Stage 4 on Metavir System) and/or complication such as ascites, bleeding varices or hepatic encephalopathy
  • Active virus (HBV) infection (hepatitis B surface antigen [HBsAg] positive).
  • Any known pre-existing psychiatric condition that could interfere with the subject's participation in and completion of the study such as:

    • Pre-existing psychiatric condition, including but not limited to moderate to severe depression, or a history of severe psychiatric disorders, such as psychosis, suicidal ideation and/or suicidal attempt
    • Severe depression includes the following:

      • Hospitalization for depression,
      • Electro convulsive therapy for depression, or
      • Depression that resulted in a prolonged absence from work and/or significant disruption of daily functions.
  • Subjects with uncontrolled hypertension and/or diabetes.
  • Alcohol consumption >50 g/day.
  • Nonprescription injection drug use in past 6 months.
  • antibody positive.
  • Previous Infliximab or other anti-TNF treatment, previous interferon; Pegylated interferon alfa-2b and ribavirin of any form.
  • impairment in cardiac or renal function, central nervous system, pulmonary, immunological, vascular and gastrointestinal disease.
  • Current (other than resected cutaneous basal, squamous cell carcinoma and/or in situ cervical cancer).
  • Use of illicit drugs which, in the investigator's opinion, may interfere with compliance with the study procedures.
  • Any other condition which, in the opinion of a physician, would make the subject unsuitable for enrollment or could interfere with the subject participating in and completing the study.
  • Have shown a previous immediate response, including anaphylaxis, to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody).
  • Have a known allergy to murine proteins or other chimeric proteins.
  • Have or have had any of the following infections within 6 months of screening: herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB.
  • Have a transplanted organ (with the exception of a corneal transplant performed > 3 months prior to screening).
  • Have a concomitant diagnosis or any history of congestive heart failure (CHF).
  • History of noncompliance to medical regimens, or other condition/circumstance that could interfere with the patient's adherence to protocol requirements (e.g., psychiatric disease, lack of motivation, travel, etc).
  • Any cause of liver disease other than chronic hepatitis C, including but not limited to:

    • Hemochromatosis
    • Alpha-1 antitrypsin deficiency
    • Wilson's disease
    • hepatitis
    • Alcoholic liver disease
    • Non-alcoholic steatohepatitis (NASH)
    • Drug-related liver disease
  • Subject with a positive TST might be enrolled if the diagnosis of tuberculosis is ruled out. To rule out TB, the following criteria must be met:
  • The medical history is negative for symptoms of TB
  • The physical examination must reveal no observations that could be related to TB
  • The patient has a documented adequate course of treatment for either LTBI or TB at least 6 months prior to screening
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Arm A

    Remicade induction dose at Day -7 prior to initiation of PEGETRON treatment for up to 48 weeks

    Drug: Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin

  • Active comparator
    Arm B

    PEGETRON treatment for up to 48 weeks

    Drug: Combination of (a) pegylated interferon alfa-2b and (b) ribavirin

Interventions

  • DrugInduction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin

    Drug pages: Peginterferon alfa-2b · Ribavirin

    1. Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy: 2. powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks 3. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks

    Also known as: (a) SCH 215596, Remicade, PEGETRON combination therapy, (b) SCH 54031, PEG-Intron, PegIntron, (c) SCH 18908, REBETOL

  • DrugCombination of (a) pegylated interferon alfa-2b and (b) ribavirin

    Drug pages: Peginterferon alfa-2b · Ribavirin

    1. Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks 2. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks

    Also known as: PEGETRON combination therapy, (a) SCH 54031, PEG-Intron; PegIntron, (b) SCH 18908, REBETOL

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who have achieved sustained virological response (SVR) in the infliximab (induction dose) plus PEGETRON and the PEGETRON groups at 24 weeks post treatment end

    Time frame: 24 weeks after completion of up to 48 weeks of PEGETRON therapy

Secondary outcomes

  1. Early virological response (EVR)

    Time frame: Week 12 of PEGETRON treatment period

  2. Safety parameters

    Time frame: During 48-week PEGETRON treatment period and 24-week follow up

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2005 to primary completion in Jun 2011, 71 months.

Of 41 industry-sponsored phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 71 months is above that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2005
First posted
Oct 12, 2005
StartActual
Jul 18, 2005
Primary completionActual
Jun 30, 2011
CompletionActual
Jun 30, 2011
Last update
Aug 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00237484
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Jul 18, 2005
Primary completion
Jun 30, 2011
Completion
Jun 30, 2011
Last update
Aug 26, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion